1 / 14

COSEHC warren trust cardiovascular fellowship

COSEHC warren trust cardiovascular fellowship. 5-YEAR REPORT 2003-2007. SELECTION CRITERIA. OBJECTIVE : To support career training and primary research individuals in cardiovascular disease in the Southeastern United States

atira
Télécharger la présentation

COSEHC warren trust cardiovascular fellowship

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. COSEHC warren trust cardiovascular fellowship 5-YEAR REPORT 2003-2007

  2. SELECTION CRITERIA OBJECTIVE: To support career training and primary research individuals in cardiovascular disease in the Southeastern United States SCIENCE FOCUS: Research broadly related to cardiovascular disease and function, stroke, or to related clinical, basic science, bioengineering and/or public health problem DISCIPLINES: All basic and clinical disciplines in medicine SITE of WORK: Fellowship and work must be at medical institution in the Southeastern United States as defined by COSEHC SCOPE OF WORK: All projects must be done in accordance with NIH guidelines for research involving animals or human research REQUIREMENTS: Completed either a MD, PhD, DrPH, or DO at time of award CITIZENSHIP: Must be a citizen or non-citizen national of the United States or must have been lawfully admitted for permanent residence (i.e., in possession of a currently valid Alien Registration Receipt Card I-551, or some other legal verification of such status). Non-citizen nationals are generally persons born in outlying possessions of the United States (e.g., American Samoa and Swains Island). Individuals on temporary or student visas are not eligible. ANNUAL AWARD: $ 3O,OOO including fringe benefits; $ 5000 may be used for project support. 65% of the funding will be given at the time of the award, with the remainder given at the completion of the fellowship, after receipt of a satisfactory final report. At least forty hours per week during the Fellowship must be dedicated to the research program.Within the 40 hours per week training period, research trainees who are also training as clinicians must devote their time to the proposed research work and must confine clinical duties to only those that are an integral part of the research training experience.

  3. SELECTION CRITERIA AWARD DURATION: ONE year. Applicant may apply for one additional year of funding at the midpoint of initial grant (by 12/30) PEER REVIEW: Prospective applicant must author application; evaluation will include applicant’s qualifications and research ability and previous accomplishments. Preference will be given to applicants trained within the southeastern US. RESTRICTIONS: Applicant can have no more than 3-years post-doctoral experience at time of the award. Must not have a faculty appointment. Institution or other funding agency may supplement fellowship award REPORTING: Progress report due at mid-term (6 months after award), and a Final report at the end of the fellowship. Publications, monographs, and manuscripts resulting from the award must acknowledge COSEHC support. SELECTION: Applications will be reviewed by the COSEHC Fellowship Committee, which will recommend a candidate to the Board for final approval *COSEHC reserves the right not to award the fellowship if, in the opinion of the fellowship review committee, there is not a suitable applicant.

  4. 2003

  5. CITATIONS 1. Zhou X, Ono H, Ono Y, Frohlich ED. Renoprotective effects of omapatrilat are mediated partially by bradykinin. Am J Nephrol. 2003 July-Aug;23:214-221. 2. Zhou X, Frohlich ED. Ageing, hypertension and the kidney: new data on an old problem. Nephrol Dial Transplant. 2003 Aug;18:1442-1445. 3. Zhou X, Ono H, Ono Y, Frohlich ED. Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model. Am J Nephrol 2004 Mar-Apr;24: 242-249. ACKNOWLEDGEMENT TO COSEHC WARREN TRUST FELLOWSHIP. 4. Zhou X, Matavelli L, Ono H, Frohlich ED. Superiority of combination of thiazide with ACE inhibitor or AT1 receptor blocker over thiazide alone on renoprotection. American Journal of Physiology 2005; 289:F871-879. 5. Zhou X, Frohlich ED. Differential effects of antihypertensive drugs on renal and glomerular hemodynamics and injury in the chronic nitric oxide suppressed rats. Am J Nephrol 2005 Mar-Apr;25:138-152. 6. Zhou X, Frohlich ED. Physiological evidence of antihypertensive renoprotection. Current Opin Cardiol. 2005 July;20:290-295. 7. Zhou X, Matavelli L, Frohlich ED. Uric acid: its relationship to renal hemodynamics and the renal renin-angiotensin system. Curr Hypertens Rep. 2006 May;8:20-124. 8. Zhou X, Frohlich ED. Cardiac and renal complications in essential hypertension: analogy with aged spontaneously hypertensive rats (SHR) or a young adult model using nitric oxide synthesis inhibition. Med Chem. 2007 Jan;3(1):61-65. 9. Zhou X, Frohlich ED. Arteriolar nephrosclerosis. Encyclopedic Reference of Molecular Mechanisms of Disease, edited by Professor Dr. Florian Lang, Springer, 2007, in press. 10. Matavelli LC, Zhou X, Frohlich ED. Hypertensive renal vascular disease and cardiovascular endpoints. Curr Opin Cardiol. 2006 July;21:305-309. 11. Matavelli LC, Zhou X, Varagic J, Susic D, Frohlich ED. Salt-loading produces severe renal hemodynamic dysfunction independent of arterial pressure in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2007 Feb;292(2):H814-9. Epub 2006 Sep 22

  6. 2004

  7. CITATIONS 1: Shi JX, Zhou MS, Kong FT, Liu J. [Clinical observation on intravenous injection of aminophyline in 52 cases with cardiac sudden arrest unresponding to epinephrine.] Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2004 Nov;16(11):690-1. Chinese. No abstract available. PMID: 15535916 [PubMed - in process] 2: Xiang QY, Liang YX, Chen BH, Wang CS, Zhen SQ, Chen LS, Zhou MS, Li JF. [Study on the application of benchmark dose and biological monitoring indexes of fluorides in drinking water] Zhonghua Yu Fang Yi Xue Za Zhi. 2004 Jul;38(4):261-4. Chinese. PMID: 15312588 [PubMed - indexed for MEDLINE] 3: Zhou MS, Schulman IH, Raij L. Nitric oxide, angiotensin II, and hypertension. Semin Nephrol. 2004 Jul;24(4):366-78. Review. PMID: 15252776 [PubMed - indexed for MEDLINE] 4: Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress. Hypertension. 2004 Aug;44(2):186-90. Epub 2004 Jul 6. PMID: 15238570 [PubMed - indexed for MEDLINE] ACKNOWLEDGEMENT TO COSEHC WARREN TRUST FELLOWSHIP.

  8. CITATIONS 5: Zhou MS, Jaimes EA, Raij L. Inhibition of oxidative stress and improvement of endothelial function by amlodipine in angiotensin II-infused rats. Am J Hypertens. 2004 Feb;17(2):167-71. PMID: 14751660 [PubMed - indexed for MEDLINE] 6: Zhou MS, Hernandez Schulman I, Pagano PJ, Jaimes EA, Raij L. Reduced NAD(P)H oxidase in low renin hypertension: link among angiotensin II, atherogenesis, and blood pressure. Hypertension. 2006 Jan;47(1):81-6. Epub 2005 Dec 12. PMID: 16344366 [PubMed - indexed for MEDLINE] 7: Zhou MS, Jaimes EA, Raij L. Vascular but not cardiac remodeling is associated with superoxide production in angiotensin II hypertension. J Hypertens. 2005 Sep;23(9):1737-43. PMID: 16093920 [PubMed - indexed for MEDLINE] 8: Schulman IH, Zhou MS, Raij L. Nitric oxide, angiotensin II, and reactive oxygen species in hypertension and atherogenesis. Curr Hypertens Rep. 2005 Feb;7(1):61-7. Review. PMID: 15683588 [PubMed - indexed for MEDLINE]

  9. CITATIONS 9: Hernandez Schulman I, Zhou MS, Raij L. Cross-talk between angiotensin II receptor types 1 and 2: potential role in vascular remodeling in humans. Hypertension. 2007 Feb;49(2):270-1. Epub 2006 Dec 11. Review. No abstract available. PMID: 17159080 [PubMed - indexed for MEDLINE] 10: Zhou MS, Jaimes EA, Raij L. Benazepril combined with either amlodipine or hydrochlorothiazide is more effective than monotherapy for blood pressure control and prevention of end-organ injury in hypertensive Dahl rats. J Cardiovasc Pharmacol. 2006 Jul;48(1):857-61. PMID: 16891915 [PubMed - indexed for MEDLINE] 11: Schulman IH, Zhou MS, Raij L. Interaction between nitric oxide and angiotensin II in the endothelium: role in atherosclerosis and hypertension. J Hypertens Suppl. 2006 Mar;24(1):S45-50. Review. PMID: 16601573 [PubMed - indexed for MEDLINE] 12: Zhou MS, Hernandez Schulman I, Pagano PJ, Jaimes EA, Raij L. Reduced NAD(P)H oxidase in low renin hypertension: link among angiotensin II, atherogenesis, and blood pressure. Hypertension. 2006 Jan;47(1):81-6. Epub 2005 Dec 12. PMID: 16344366 [PubMed - indexed for MEDLINE]

  10. CITATIONS 13: Sierra-Alvarez R, Hollingsworth J, Zhou MS. Removal of copper in an integrated sulfate reducing bioreactor-crystallization reactor system. Environ Sci Technol. 2007 Feb 15;41(4):1426-31. PMID: 17593752 [PubMed - indexed for MEDLINE] 14: Schulman IH, Zhou MS, Jaimes EA, Raij L. Dissociation between metabolic and vascular insulin resistance in aging. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H853-9. Epub 2007 Apr 13. PMID: 17434977 [PubMed - indexed for MEDLINE] 15: Zhou MS. Upregulation of nitric oxide, inhibition of oxidative stress, and antihypertensive effects of statins. Hypertension. 2007 Jun;49(6):e43; author reply e44. Epub 2007 Apr 2. No abstract available. PMID: 17404175 [PubMed - indexed for MEDLINE] 16: Hernandez Schulman I, Zhou MS, Raij L. Cross-talk between angiotensin II receptor types 1 and 2: potential role in vascular remodeling in humans. Hypertension. 2007 Feb;49(2):270-1. Epub 2006 Dec 11. Review. No abstract available. PMID: 17159080 [PubMed - indexed for MEDLINE]

  11. 2005 (6 months)

  12. CITATIONS 1: Botros FT, Schwartzman ML, Stier CT Jr, Goodman AI, Abraham NG. Increase in heme oxygenase-1 levels ameliorates renovascular hypertension. Kidney Int. 2005 Dec;68(6):2745-55. PMID: 16316349 [PubMed - indexed for MEDLINE] 2: Olszanecki R, Rezzani R, Omura S, Stec DE, Rodella L, Botros FT, Goodman AI, Drummond G, Abraham NG. Genetic suppression of HO-1 exacerbates renal damage: reversed by an increase in the antiapoptotic signaling pathway. PMID: 16940561 [PubMed - indexed for MEDLINE] 3: Botros FT, Navar LG. Interaction between endogenously produced carbon monoxide and nitric oxide in regulation of renal afferent arterioles. Am J Physiol Heart Circ Physiol. 2006 Dec;291(6):H2772-8. Epub 2006 Jul 14. PMID: 16844915 [PubMed - indexed for MEDLINE] 4: Botros FT, Olszanecki R, Prieto-Carrasquero MC, Goodman AI, Navar LG, Abraham NG. Induction of heme oxygenase-1 in renovascular hypertension is associated with inhibition of apoptosis. Cell Mol Biol (Noisy-le-grand). 2007 May 15;53(4):51-60. PMID: 17531161 [PubMed - indexed for MEDLINE] ACKNOWLEDGEMENT TO COSEHC WARREN TRUST FELLOWSHIP 5: Mitchell KD, Botros FT, Navar LG. Intrarenal renin-angiotensin system and counteracting protective mechanisms in angiotensin II-dependent hypertension. Acta Physiol Hung. 2007 Mar;94(1-2):31-48. Review. PMID: 17444274 [PubMed - indexed for MEDLINE] ACKNOWLEDGEMENT TO COSEHC WARREN TRUST FELLOWSHIP

  13. 2006

  14. 2007

More Related